Almirall notes "good traction in Europe" for psoriasis cream Wynzora
The Spanish skin health firm’s psoriasis business continues to grow in H1, driven in part by the cream dubbed Wynzora, which was developed by MC2 Therapeutics.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
Psoriasis cream Wynzora has gotten off to a flying start on the European market, winning 7% and 6% market shares in Germany and Spain, respectively, reports the Spanish dermatology firm that sells the treatment, Almirall, in connection with its H1 report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
